CoChat
Sign Up
Cited by 62Attention Deficit Hyperactivity DisorderPharmaceutical studies and practicesPharmacology and Obesity Treatment

Effects of Atomoxetine on Growth After 2-Year Treatment Among Pediatric Patients With Attention-Deficit/Hyperactivity Disorder

Spencer, Thomas J., Newcorn, Jeffrey H., Kratochvil, Christopher J., Ruff, Dustin, Michelson, David, Biederman, Joseph·2005·Pediatrics
DOI 10.1542/peds.2004-0624
Open this paper in CoChat — free account

Abstract

Objective. Treatment for attention-deficit/hyperactivity disorder is maintained typically over periods of months or years and, as a result, the potential effects on growth of pharmacotherapy for this disorder have been an area of concern. This meta-analysis examined the effect on growth of atomoxetine, now approved in the United States for the treatment of attention-deficit/hyperactivity disorder. Methods. Patients (N = 412) were 6 to 16 years of age at the start of the treatment period and received atomoxetine treatment (maximal dose: 1.8 mg/kg per day) for ≥2 years. Weight and height measurements were analyzed both as actual values and after conversion to percentiles and z scores with growth charts from the Centers for Disease Control and Prevention. Expected weight and height at the end point were calculated through extrapolation from patients' baseline percentiles with the growth charts. Results. Results indicated that, after 2 years, observed weight and height were close to those predicted on the basis of the patients' baseline weight and height. Weight increased an average of 10.8 kg, a decrease relative to baseline normative weight of 2.7 percentiles, corresponding to 0.87 kg. Height increased an average of 13.3 cm, a decrease relative to baseline normative heights of 2.2 percentiles, corresponding to 0.44 cm. For both weight and height, the quartile of patients who were smallest at baseline had an increase in end-point percentile, whereas patients in the highest quartile had a decrease. Conclusions. These findings suggested that, at the group level, there was only a minimal effect on height after 2 years of treatment with atomoxetine and, for patients most at risk (the lowest quartile), there seemed to be no effect.

Integrity signals

Registry

Crossref · 10.1542/peds.2004-0624

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Small effects on growth were seen for atomoxetine during the first 2 years of treatment; but in those who received prolonged treatment for up to 5 years no long-term effects on growth were apparent apart from an overweight subgroup.

    “Small effects were seen for atomoxetine during the first 2 years of treatment; but in those who received prolonged treatment for up to 5 years no long-term effects on growth were apparent apart from an overweight subgroup [133, 134].”

    From European guidelines on managing adverse effects of medication for ADHD (2011) · cites this paper as [134]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Spencer, T. J., Newcorn, J. H., Kratochvil, C. J., Ruff, D., Michelson, D., & Biederman, J.
Affiliations
  • Harvard University (US)
  • Mount Sinai Medical Center, New York, New York
  • University of Nebraska Medical Center (US)
  • Eli Lilly (United States) (US)
ORCID
Venue
Pediatrics
Publisher
American Academy of Pediatrics (AAP)
Published
2005-07-01
Volume
116
Issue
1
Pages
e74-e80
ISSN
  • 0031-4005 (ISSN-L)
  • 1098-4275
DOI
10.1542/peds.2004-0624
OpenAlex
W1980333466
Cited by
62
References
21
Citations by year
2025: 1 · 2022: 2 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 2 · 2015: 1 · 2013: 4 · 2012: 5
FWCI
4.81
Type
journal article
Language
en
Open access
closed
Locations
  • PEDIATRICS (publishedVersion)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
Keywords
atomoxetine, attention deficit hyperactivity disorder, pediatric patients, growth, weight, height, long-term pharmacotherapy, stimulant medication, growth charts
MeSH terms
Atomoxetine Hydrochloride, Adolescent, Attention Deficit Disorder with Hyperactivity, Body Height, Child, Growth, Humans, Propylamines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review